The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Tislelizumab +Bevacizumab+pc for Untreated EGFR+ and High PD-L1 Non-squamous NSCLC
Official Title: Efficacy and Safety of Tislelizumab Combined With Bevacizumab and Platinum Plus Pemetrexed for Untreated EGFR+ and High PD-L1 Expression Non-squamous NSCLC :a Phase II, Single-center, Single Arm Study
Study ID: NCT05394233
Brief Summary: A study to evaluate the efficacy and safety of tislelizumab combined with bevacizumab and platinum-based pemetrexed in the treatment of naïve patients with advanced non-squamous non-small cell lung cancer with sensitive EGFR mutations and high PD-L1 expression Prospective, open-label, single-arm phase II clinical study
Detailed Description: A study to evaluate the efficacy and safety of tislelizumab combined with bevacizumab and platinum-based pemetrexed in the treatment of naïve patients with advanced non-squamous non-small cell lung cancer with sensitive EGFR mutations and high PD-L1 expression Prospective, open-label, single-arm phase II clinical study; Research purposes: Main purpose: To evaluate the median progression-free rate of tislelizumab combined with bevacizumab and platinum pemetrexed in treatment-naïve advanced non-small cell lung cancer patients with sensitive EGFR mutations and high PD-L1 expression Survival (middle progression free survival, mPFS) Secondary purpose: * Evaluation of objective response rate (ORR) according to RECIST version 1.1; * Evaluation of disease control rate (DCR) according to RECIST version 1.1; * Assess overall survival (OS); * Assess Duration of Response (DOR); * Evaluate the safety of the treatment using NCI-CTCAE v5; Exploratory Purpose: • Assess potential predictive biomarkers.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Sichuan Cancer Hospital, Chengdu, Sichuan, China
Sichuan Cancer Hospital, Chengdu, Sichuan, China
Sichuan Cancer Hospital, Chengdu, Sichuan, China
Name: juan li
Affiliation: Sichuan Cancer Hospital Chengdu, Sichuan China
Role: STUDY_DIRECTOR